Outcomes reported by patients during de-intensification of complex insulin therapy regimens for type 2 diabetes mellitus

In modern diabetology, there is a growing interest in patient-reported outcomes (COI) as an important indicator influencing the effectiveness of therapy. This review analyzes the effect of de-intensification of complex insulin therapy regimens using the drug Iglarlixi (a combination of insulin glargine 100 U/ml and lixisenatide) on the quality of life and satisfaction with treatment in patients with type 2 diabetes mellitus (T2DM). The results of key studies (SoliSwitch, IDEAL, SIMPLIFY Japan) are reviewed, demonstrating a significant improvement in COI indicators when switching from multiple injections of insulin or ready-made mixtures to a single injection of Iglarlixi. The most pronounced improvements were noted in the domains “Burden of treatment” and “Diabetes management”. Given the influence of psychosocial factors on the perception of therapy and treatment adherence, de-intensification of insulin therapy may be especially important for patients experiencing stigmatization and diabetic distress. The review results confirm that switching to Iglarlixi is an effective de-intensification strategy that improves both glycemic control and quality of life in patients with T2DM.